



1

2 **Supplementary Figure 1. Rheological characterization of polyacrylamide (PAM) gels.**
 3 Strain, frequency and time sweeps of **A)** stiff and **B)** soft PAM gels showing storage (G') and
 4 loss (G'') moduli. **C)** Young's modulus of soft and stiff PAM gels. Data is shown as mean \pm
 5 SEM for $n=12$. **D)** Mean fluorescent intensity of collagen-I immunolocalisation. Data is
 6 shown as mean \pm SEM for $n>15$ images taken across 3 separate gels.



7
 8 **Supplementary Figure 2. Analysis of morphology in response to substrate stiffness and**
 9 **RhoA signalling. A) Staining of hMSC structure showing actin (green), nuclei (blue) and non-**
 10 **muscle myosin II (red). Scale bar, 50 μm . Histograms showing B) cell spread area, C) aspect**
 11 **ratio and D) circularity for populations of >50 MSCs per condition.**




12

13 **Supplementary Figure 3. Hierarchical clustering of miRNA sequencing samples.**


14

15



16

17 **Supplementary Figure 4. Effect of miRNA modulation on MSC differentiation bias for individual**
 18 **MSC donors.** Effect of miRNA mimics and inhibitors on MSCs cultured on **A)** 70kPa and **B)** 0.6kPa
 19 substrates. Data is shown as mean change in proportion of osteoblasts relative to control \pm SD.
 20 Statistically different samples are denoted by $p < 0.05$ (*), 0.01 (**), and 0.001 (***).





21

22

23 **Supplementary Figure 5. Expression analysis of mTOR pathway components in response to**
 24 **substrate stiffness and RhoA signalling. A)** Quantification of proteins in MSCs cultured on
 25 70 kPa, 70 kPa + C3T or 0.6 kPa substrates. Data are expressed as relative pixel density units,
 26 all graphs show mean \pm SEM for 3 independent hMSC donors. qPCR determination of the
 27 relative expression of miRNA target genes for B) *miR-100-5p* and C) *miR-143-3p*. All data is
 28 represented as mean \pm SEM relative to expression in 70 kPa samples. Statistically different
 29 samples are denoted by $p < 0.05$ (*), 0.01 (**), and 0.001 (***)).

30



31


32

33 **Supplementary Figure 6. Expression analysis of mTOR pathway components in response to miRNA**
 34 **mimics/inhibitors or rapamycin treatment.** Quantification of proteins in **A)** MSCs transfected
 35 with miRNA mimics or inhibitors and **B)** MSCs treated with 50 nM rapamycin. Data are
 36 expressed as relative pixel density units, all graphs show mean \pm SEM for 3 independent
 37 hMSC donors.

38

39

40



41

42 **Supplementary Figure 7. Opposing effects of miRNA inhibitors and Rapamycin on MSC**
43 **differentiation bias.** Data shown for 3 independent MSC donors for untreated (black bars) and
44 rapamycin treated (grey bars) MSCs. Data is shown as mean change in proportion of osteoblasts
45 relative to control \pm SD. Statistically different samples are denoted by $p < 0.05$ (*), 0.01 (**)
46 and 0.001 (***)).

47

48

Fig. 4A




Fig. 4B






Fig. 4G



49

50 **Supplementary Figure 8.** Full scans of uncropped Western blots presented in the main figure.

52 **Supplementary Table 1. miRNAs upregulated in 70 kPa + C3T vs 70 kPa.**

miRNA	logFC	logCPM	P Value	FDR
<i>hsa-mir-3929-3p</i>	5.5759784	5.353010	1.101922e-13	5.774073e-11
<i>hsa-mir-3929</i>	4.4738797	5.569399	8.551213e-12	2.240418e-09
<i>hsa-mir-5096-3p</i>	2.5543970	5.970366	3.714409e-07	4.865875e-05
<i>hsa-mir-619-5p</i>	4.1287945	7.014513	3.289117e-06	3.173089e-04
<i>hsa-mir-566-5p</i>	2.7488159	4.667838	7.156853e-06	5.357416e-04
<i>hsa-mir-1285-1-5p</i>	3.4135330	5.047673	1.481225e-04	9.702022e-03
<i>hsa-mir-5096</i>	2.8533990	4.208759	2.562158e-04	1.464287e-02
<i>hsa-mir-7851-5p</i>	5.5239765	5.879177	2.794442e-04	1.464287e-02
<i>hsa-mir-5096-5p</i>	2.0439955	5.276739	3.451199e-04	1.644026e-02
<i>hsa-mir-1273d-3p</i>	2.3882644	4.214999	4.330409e-04	1.890945e-02
<i>hsa-mir-3159-3p</i>	2.0467889	5.990651	6.318541e-04	2.364939e-02
<i>hsa-mir-4419a</i>	1.9017001	4.599033	7.185424e-04	2.510108e-02
<i>hsa-mir-483-5p</i>	2.2338434	4.222222	1.530696e-03	4.595441e-02
<i>hsa-mir-566-3p</i>	2.3271466	5.025884	1.578587e-03	4.595441e-02

53

54

55 **Supplementary Table 2. miRNAs downregulated in 70 kPa + C3T vs 70 kPa.**

miRNA	logFC	logCPM	P Value	FDR
<i>hsa-mir-335-3p</i>	-1.7669778	8.529429	3.214541e-08	5.614732e-06
<i>hsa-mir-100-5p</i>	-0.2792123	17.803562	3.633308e-06	3.173089e-04
<i>hsa-mir-7974-3p</i>	-2.6368929	4.672177	5.227040e-04	2.106899e-02
<i>hsa-mir-1268b-5p</i>	-1.6934567	6.626036	9.941078e-04	3.255703e-02

56

57

58 **Supplementary Table 3. miRNAs upregulated in 0.6 kPa vs 70 kPa.**

miRNA	logFC	logCPM	P Value	FDR
<i>hsa-mir-122-5p</i>	3.245741	5.981104	1.452461e-08	7.610898e-06
<i>hsa-mir-4448-3p</i>	1.444811	9.031696	1.041214e-04	2.727979e-02

59

60

61 **Supplementary Table 4. miRNAs upregulated in 0.6 kPa vs 70 kPa + C3T.**

miRNA	logFC	logCPM	P Value	FDR
<i>hsa-mir-100-5p</i>	0.2974540	17.803562	8.222047e-08	8.616706e-06
<i>hsa-mir-6131-3p</i>	1.0783050	15.120294	3.546137e-06	2.322720e-04
<i>hsa-mir-4448-3p</i>	1.5794037	9.031696	2.989968e-05	1.424312e-03
<i>hsa-mir-1180-3p</i>	0.9887903	8.566305	7.971763e-05	3.213234e-03
<i>hsa-mir-7706-3p</i>	1.6518474	6.740006	2.252161e-04	6.211222e-03
<i>hsa-mir-25-5p</i>	2.0540046	5.784007	5.785608e-04	1.263191e-02
<i>hsa-mir-3615-3p</i>	0.8177897	8.702686	6.258842e-04	1.311853e-02
<i>hsa-mir-122-5p</i>	1.6418679	5.981104	1.083907e-03	1.893225e-02
<i>hsa-mir-3687-3p</i>	1.9865586	5.323219	1.959968e-03	3.209447e-02
<i>hsa-mir-320b-2-3p</i>	0.7504807	8.693615	2.212632e-03	3.410056e-02
<i>hsa-mir-7974-3p</i>	2.3248083	4.672177	3.574127e-03	4.928533e-02

62

63

64 **Supplementary Table 5. miRNAs downregulated in 0.6 kPa vs 70 kPa + C3T**

miRNA	logFC	logCPM	P Value	FDR
<i>hsa-mir-3929-3p</i>	-4.4900459	5.353010	1.024551e-12	3.465906e-10
<i>hsa-mir-3929</i>	-4.2621572	5.569399	1.322865e-12	3.465906e-10
<i>hsa-mir-619-5p</i>	-4.2848277	7.014513	2.453039e-08	4.284641e-06
<i>hsa-mir-5096-3p</i>	-2.5041362	5.970366	4.044641e-08	5.298480e-06
<i>hsa-mir-566-5p</i>	-3.2134090	4.667838	1.694976e-07	1.480279e-05
<i>hsa-mir-5096</i>	-3.8722842	4.208759	8.528787e-07	6.384406e-05
<i>hsa-mir-21-5p</i>	-0.6454914	16.389694	8.286239e-06	4.824433e-04
<i>hsa-mir-5096-5p</i>	-2.3107125	5.276739	1.906115e-05	9.988041e-04
<i>hsa-mir-3159-3p</i>	-2.1983740	5.990651	4.601951e-05	2.009519e-03
<i>hsa-mir-660-5p</i>	-2.0389909	6.124728	9.497978e-05	3.554958e-03
<i>hsa-mir-1273d-3p</i>	-2.5101363	4.214999	1.328769e-04	4.641833e-03
<i>hsa-mir-1285-1-5p</i>	-2.9187077	5.047673	1.518824e-04	4.974150e-03
<i>hsa-mir-7851-5p</i>	-4.5803584	5.879177	1.868686e-04	5.618112e-03
<i>hsa-mir-382-3p</i>	-1.4297022	7.143209	1.929886e-04	5.618112e-03
<i>hsa-mir-136-3p</i>	-2.5662955	4.665143	3.089401e-04	7.978467e-03
<i>hsa-mir-337-3p</i>	-1.5090304	6.466167	3.197477e-04	7.978467e-03
<i>hsa-mir-146a-5p</i>	-2.2848487	6.080851	4.821789e-04	1.148462e-02
<i>hsa-mir-186-5p</i>	-1.0251221	7.834047	5.105812e-04	1.163237e-02
<i>hsa-mir-140-5p</i>	-1.1710280	-1.1710280	7.787207e-04	1.569422e-02
<i>hsa-mir-1273a-5p</i>	-2.0655408	4.491878	8.283748e-04	1.607661e-02
<i>hsa-mir-21-3p</i>	-1.4118082	6.715625	8.713034e-04	1.630582e-02
<i>hsa-mir-376c-3p</i>	-1.7264774	5.206281	9.740389e-04	1.759988e-02
<i>hsa-mir-34a-5p</i>	-1.2188259	7.278523	1.678721e-03	2.837581e-02

<i>hsa-mir-494-3p</i>	-0.8668309	8.376215	2.132062e-03	3.385456e-02
<i>hsa-mir-195-5p</i>	-1.7854635	4.869119	2.437922e-03	3.649918e-02
<i>hsa-mir-8086-3p</i>	-2.5630816	6.122087	3.222029e-03	4.689842e-02
<i>hsa-mir-656-3p</i>	-2.1238426	4.190869	3.449753e-03	4.885597e-02

65

66

67 **Supplementary Table 6. miRNAs upregulated in [70 kPa + C3T and 0.6 kPa] vs 70 kPa.**

miRNA	logFC	logCPM	P Value	FDR
<i>hsa-mir-3929-3p</i>	4.34775	5.35301	3.03E-09	1.59E-06
<i>hsa-mir-3929</i>	3.2717	5.569399	9.51E-08	2.49E-05
<i>hsa-mir-122-5p</i>	2.770195	5.981104	7.97E-07	1.04E-04
<i>hsa-mir-619-5p</i>	2.915437	7.014513	2.79E-04	2.92E-02
<i>hsa-mir-5096-3p</i>	1.583912	5.970366	5.19E-04	4.53E-02

68

69

70 **Supplementary Table 7. miRNAs downregulated in [70 kPa + C3T and 0.6 kPa] vs 70 kPa.**

miRNA	logFC	logCPM	P Value	FDR
<i>hsa-mir-335-3p</i>	-1.236386	8.529429	3.26E-07	5.69E-05

71

72

73 **Supplementary Table 8. miRNAs upregulated in 0.6 kPa vs [70 kPa and 70 kPa + C3T].**

miRNA	logFC	logCPM	P Value	FDR
<i>hsa-mir-3929-3p</i>	3.433864	5.35301	5.61E-09	1.97E-06
<i>hsa-mir-3929</i>	3.2540579	5.569399	7.50E-09	1.97E-06
<i>hsa-mir-619-5p</i>	3.3575916	7.014513	1.81E-06	1.58E-04
<i>hsa-mir-21-5p</i>	0.5578685	16.389694	7.11E-06	5.32E-04
<i>hsa-mir-5096-3p</i>	1.6641658	5.970366	4.96E-05	3.25E-03
<i>hsa-mir-566-5p</i>	2.2932767	4.667838	8.58E-05	5.00E-03
<i>hsa-mir-660-5p</i>	1.7911026	6.124728	1.23E-04	6.42E-03
<i>hsa-mir-5096</i>	2.960036	4.208759	1.35E-04	6.42E-03
<i>hsa-mir-382-3p</i>	1.171821	7.143209	4.40E-04	1.92E-02
<i>hsa-mir-136-3p</i>	2.1956999	4.665143	4.82E-04	1.94E-02
<i>hsa-mir-494-3p</i>	0.7947635	8.376215	1.08E-03	3.76E-02
<i>hsa-mir-5096-5p</i>	1.5545034	5.276739	1.29E-03	4.13E-02
<i>hsa-mir-7851-5p</i>	3.6124295	5.879177	1.34E-03	4.13E-02
<i>hsa-mir-21-3p</i>	1.1892173	6.715625	1.43E-03	4.17E-02
<i>hsa-mir-143-3p</i>	0.6391022	15.017312	1.70E-03	4.46E-02
<i>hsa-mir-337-3p</i>	1.144301	6.466167	2.06E-03	4.75E-02
<i>hsa-mir-186-5p</i>	0.7785284	7.834047	2.08E-03	4.75E-02

74

75

76 **Supplementary Table 9. miRNAs downregulated in 0.6 kPa vs [70 kPa and 70 kPa + C3T]**

miRNA	logFC	logCPM	P Value	FDR
<i>hsa-mir-122-5p</i>	-2.3200241	5.981104	5.40E-08	9.44E-06
<i>hsa-mir-4448-3p</i>	-1.5091103	9.031696	3.32E-07	4.34E-05
<i>hsa-mir-6131-3p</i>	-0.9025831	15.120294	1.21E-06	1.26E-04
<i>hsa-mir-100-5p</i>	-0.1509109	17.803562	9.99E-04	3.74E-02
<i>hsa-mir-320b-2-3p</i>	-0.6169668	8.693615	1.60E-03	4.41E-02
<i>hsa-mir-320a-5p</i>	-1.3021374	6.746814	2.05E-03	4.75E-02

77

78

79 **Supplementary Table 10. Composition for polyacrylamide (PAM) hydrogels.**

	Soft (0.6 kPa) PAM gels	Stiff (70 kPa) PAM gels
Acrylamide [30%]	50 μ l	200 μ l
Bis-Acrylamide [1%]	75 μ l	300 μ l
dH ₂ O	375 μ l	N/A
TEMED	1.25 μ l	1.25 μ l
APS [10%]	3.75 μ l	3.75 μ l

80 *APS: ammonium persulfate. TEMED: N, N, N', N'-Tetramethylethylenediamine.*

81 **Supplementary Table 11. qPCR forward and reverse primer sequences used in this study.**

	Forward 5'-3'	Reverse 3'-5'
<i>GAPDH</i>	ATGGGGAAGGTGAAGGTCG	TAAAAGCAGCCCTGGTGACC
<i>RPS27a</i>	TGGATGAGAATGGCAAATTAGTC	CACCCCAGCACCACATTCA
<i>mTOR</i>	CAGAAGGTGGAGGTGTTTGAG	TGACATGACCGCTAAAGAACG
<i>TRIB1</i>	TTGGGGACATGCACTCCTATG	GGCGGAGACAATCTGCTTGA
<i>TRIB2</i>	GACTCCGAACCTTGTCGCATTG	GGCACGAAAAACGTGGTCT
<i>THAP2</i>	GGCTGTGCCACTACCTACAAC	CAGGCGAACCCATTCTTTTCTT
<i>RICTOR</i>	AGAAGCACGATTTCTAGCCAGT	AGTAGACCTCGCCTTATTTCCA
<i>LARP1</i>	GGTTCAGCAAGTTCCTAC	ATCCAGTGTCCGTCCTTC

82 *GAPDH: glyceraldehyde-3-phosphate dehydrogenase. RPS27a: ribosomal protein S27a.*
83 *mTOR: mechanistic target of rapamycin. TRIB1: tribbles pseudokinase 1. TRIB2: tribbles*
84 *pseudokinase 2. THAP2: THAP domain containing 2. RICTOR: RPTOR independent companion*
85 *of MTOR complex 2. LARP1: La ribonucleoprotein domain family member 1.*

86

87 **Supplementary Table 12. Details of Exiqon miRNA mimics and miR inhibitors used in this**
 88 **study.**

	miRNA mimic	miRNA inhibitor
Mimic negative control, FAM labelled	479995-011	-
miRNA inhibitor control, FITC labeled	-	199006-011
<i>hsa-miR-100-5p</i>	472477-001	4104079-001
<i>hsa-miR-122-5p</i>	470430-001	4104657-001
<i>hsa-miR-143-3p</i>	470035-001	4101245-001
<i>hsa-miR-21-5p</i>	473093-001	4102261-001
<i>hsa-miR-335-3p</i>	472642-001	4103230-001

89

90